Silence Therapeutics/$SLN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Silence Therapeutics
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
- Ticker
- $SLN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 88
- Headquarters
- London, United Kingdom
- Website
- www.silence-therapeutics.com
SLN Metrics
BasicAdvanced
$641m
-
-$1.28
-
-
Price and volume
Market cap
$641m
52-week high
$17.58
52-week low
$4.19
Average daily volume
1.3m
Financial strength
Current ratio
7.416
Quick ratio
6.398
Long term debt to equity
0.023
Total debt to equity
0.291
Profitability
EBITDA (TTM)
-63.944
Gross margin (TTM)
85.85%
Net profit margin (TTM)
-9,748.46%
Operating margin (TTM)
-10,475.61%
Effective tax rate (TTM)
-0.00%
Revenue per employee (TTM)
$10,000
Management effectiveness
Return on assets (TTM)
-29.65%
Return on equity (TTM)
-90.41%
Valuation
Price to revenue (TTM)
1,043.011
Price to book
16.68
Price to tangible book (TTM)
22.99
Growth
Revenue change (TTM)
-97.74%
Earnings per share change (TTM)
-23.89%
3-year revenue growth (CAGR)
-74.70%
3-year earnings per share growth (CAGR)
-6.48%
10-year earnings per share growth (CAGR)
11.96%
SLN News
AllArticlesVideos
Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering
Business Wire2 days ago
Silence Therapeutics' Divesiran Hits Phase II Goal, Sets Up Phase III PV Trial
MarketBeat3 days ago
Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares
Business Wire3 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.